Market Opportunity Assessment Study: Netupitant - Palonosetron FDC is Expected to Reach USD 515.0 Million in 2018: Transparency Market Research

Market Opportunity Assessment Study: Netupitant - Palonosetron FDC is Expected to Reach USD 515.0 Million in 2018: Transparency Market Research PR Newswire ALBANY, New York, October 24, 2012 ALBANY, New York, October 24, 2012 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Netupitant - Palonosetron FDC - Global Market Opportunity Assessment Study, 2012 - 2018", the global Netupitant - Palonosetron FDC sales are expected to reach USD 515.0 million by 2018. The global Chemotherapy-induced nausea and vomiting (CINV) market is estimated to reach USD 1.7 billion by 2015 at a growth rate of 7.1%, whereas country such as South Africa is estimated to constitute 9% of the CINV market by 2015, due to prevalent cancer related conditions and subsequent increase in CINV patient pool. Asian region is expected to witness largest patient share for CINV contributing majorly to the total CINV patient pool. Hence, Asian market is expected to have huge growth potential for Netupitant - Palonosetron FDC. Browse the full report at http://www.transparencymarketresearch.com/netupitant-palonosetron-fdc- market.html Chemotherapy is one of the treatment options utilized by oncologists in treating different types of cancers. Nausea and vomiting are the most common side-effects experienced by cancer patients when administered with chemotherapy.